Correction: 2021 DORIS definition of remission in SLE: final recommendations from an international task force
- PMID: 35135871
- PMCID: PMC8830288
- DOI: 10.1136/lupus-2021-000538corr1
Correction: 2021 DORIS definition of remission in SLE: final recommendations from an international task force
Erratum for
-
2021 DORIS definition of remission in SLE: final recommendations from an international task force.Lupus Sci Med. 2021 Nov;8(1):e000538. doi: 10.1136/lupus-2021-000538. Lupus Sci Med. 2021. PMID: 34819388 Free PMC article.
Similar articles
-
2021 DORIS definition of remission in SLE: final recommendations from an international task force.Lupus Sci Med. 2021 Nov;8(1):e000538. doi: 10.1136/lupus-2021-000538. Lupus Sci Med. 2021. PMID: 34819388 Free PMC article.
-
Remission in SLE-do DORIS criteria match the treating physician's judgment? A cross-sectional study to assess reasons for discordance.Rheumatology (Oxford). 2021 Sep 1;60(9):4298-4305. doi: 10.1093/rheumatology/keab005. Rheumatology (Oxford). 2021. PMID: 33493321
-
Correction: Targeting DORIS Remission and LLDAS in SLE: A Review.Rheumatol Ther. 2024 Aug;11(4):1059-1061. doi: 10.1007/s40744-024-00679-w. Rheumatol Ther. 2024. PMID: 38847996 Free PMC article. No abstract available.
-
[Treat to target in systemic lupus erythematosus].Z Rheumatol. 2020 May;79(4):351-358. doi: 10.1007/s00393-020-00771-w. Z Rheumatol. 2020. PMID: 32232548 Review. German.
-
Treat-to-target in systemic lupus erythematosus: Where are we?Eur J Intern Med. 2020 Apr;74:29-34. doi: 10.1016/j.ejim.2020.01.018. Epub 2020 Feb 1. Eur J Intern Med. 2020. PMID: 32014364 Review.
Cited by
-
Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study.RMD Open. 2025 Jan 6;11(1):e005118. doi: 10.1136/rmdopen-2024-005118. RMD Open. 2025. PMID: 39762120 Free PMC article.
-
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.Ann Rheum Dis. 2024 Mar 12;83(4):464-474. doi: 10.1136/ard-2023-224919. Ann Rheum Dis. 2024. PMID: 38233103 Free PMC article.
-
Clinical trial outcomes for SLE: what we have and what we need.Lupus Sci Med. 2024 Feb 15;11(1):e001114. doi: 10.1136/lupus-2023-001114. Lupus Sci Med. 2024. PMID: 38360028 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources